ImmunoGen, Inc. (IMGN)
IMGN moved a median of +0.07% 30 minutes after news, and +0.17% by the close. How IMGN actually reacts to news — the realized, point-in-time move the market made, measured across 140 labeled events over the last three years with zero look-ahead.
IMGN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 99 |
| 30-min | +0.07% | 56% | 99 |
| 60-min | +0.05% | 54% | 99 |
| to close | +0.17% | 60% | 99 |
| Middle 50% of IMGN reactions | -0.22% to +0.32% |
|---|---|
| Median reaction (30-min) | +0.07% |
| Measured reactions | 140 |
Half of all ImmunoGen, Inc. news events land between -0.22% and +0.32% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IMGN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 20 | +0.03% | 55% | +0.40% |
| Coverage initiations | 19 | -0.22% | 37% | -0.27% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how IMGN ranks against every other measured name →
That’s how IMGN usually reacts — get an email when it moves on news →Email me when IMGN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IMGN's baseline. Nothing else.
Recent IMGN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Seaport Therapeutics Names Lauren White as Chief Financial Officer | Press release | Business Wire | — | — | |
| Form 15-12G ImmunoGen, Inc. | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form 8-K ImmunoGen, Inc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form S-8 POS ImmunoGen, Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K ImmunoGen, Inc. For: Feb 07 | SEC filing · Form 8-K | SEC EDGAR | -0.02% | +0.00% | |
| ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.02% | -0.34% | |
| Form 8-K ImmunoGen, Inc. For: Jan 31 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | +0.03% | |
| Form 8-K ImmunoGen, Inc. For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | -0.30% | |
| Form DEFA14A ImmunoGen, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.09% | -0.30% | |
| Form 8-K ImmunoGen, Inc. For: Jan 24 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | -0.20% | |
| Form DEFA14A ImmunoGen, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.09% | -0.20% | |
| Form 8-K ImmunoGen, Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +0.50% | +0.13% | |
| Form DEFA14A ImmunoGen, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.50% | +0.13% | |
| ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.29% | -0.34% | |
| Form DEFM14A ImmunoGen, Inc. | SEC filing · Form DEFM14A | SEC EDGAR | +0.00% | -0.44% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGN, HA, CERE, HOLI | Press release | GlobeNewswire | -0.07% | +0.34% | |
| Form DEFA14A ImmunoGen, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.07% | +0.07% | |
| Form PREM14A ImmunoGen, Inc. For: Jan 31 | SEC filing · Form PREM14A | SEC EDGAR | -0.37% | +0.00% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGN, HA, EAR | Press release | GlobeNewswire | -0.13% | -1.04% | |
| Lifshitz Law PLLC Announces Investigations of IMGN, HA, CERE, and EVFM | Press release | Accesswire | -0.13% | -1.04% | |
| ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH | Press release | Business Wire | +0.03% | +1.40% | |
| FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer | Press release | Business Wire | +0.00% | +0.21% | |
| ALERT: Juan Monteverde Encourages the Shareholders of IMGN, FRLN, PATI to Take Action | Press release | Accesswire | +0.03% | +1.12% | |
| ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.29% | +0.41% | |
| Form 8-K ImmunoGen, Inc. For: Nov 30 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | +0.27% | |
| Form DEFA14A ImmunoGen, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.45% | +0.27% | |
| IMGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ImmunoGen, Inc. Is Fair to Shareholders | Press release | Business Wire | -0.03% | +0.51% | |
| Form 10-Q ImmunoGen, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.09% | +2.71% | |
| Form 8-K ImmunoGen, Inc. For: Nov 02 | SEC filing · Form 8-K | SEC EDGAR | +2.17% | -1.27% | |
| ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference | Press release | Business Wire | -3.09% | +2.71% | |
| ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results | Press release | Business Wire | +2.17% | -1.27% | |
| ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +2.17% | -1.27% | |
| ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer | Press release | Business Wire | +0.87% | +0.54% | |
| ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results | Press release | Business Wire | -1.43% | -3.94% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IMGN section they belong to.
Where else IMGN is measured.
IMGN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| InflaRx N.V. (IFRX) | 142 | 0.00% | 48% |
| Oncocyte Corporation (OCX) | 141 | 0.00% | 47% |
| MEDIFIRST SOLUTIONS (MFST) | 140 | 0.00% | 47% |
| Pro-Dex, Inc. (PDEX) | 140 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ImmunoGen, Inc.'s median reaction calculated?
Every labeled IMGN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 140 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 56% of IMGN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IMGN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.